In a work published in 2020, an in vivo CRISPR screening, performed using mouse clonal congenic primary tumour cell lines, identified lysine demethylase 3A (KDM3A) as a potent epigenetic regulator of immunotherapy response in PC. Here, KDM3A is linked to neoplasm.